Peter Tassiopoulos

About Peter Tassiopoulos

Peter Tassiopoulos, 55, has served as Director and Chief Executive Officer of ALT5 Sigma Corporation since August 2024. He brings 30+ years of leadership across healthcare, finance, and technology, with over $1 billion in completed M&A, divestitures, and financings; from April 2022 to August 2024 he worked as an independent M&A consultant, restructuring >$150 million of debt and facilitating a $35 million asset purchase for a Canadian public company .

Past Roles

External Roles

Board Governance

• Independence: Not independent; ALT5 discloses independent directors as Butler, Bitar, Hajjar, and Pitters — excluding Tassiopoulos given his CEO role .
• Committee assignments: Audit (Bitar, Butler—Chair, Hajjar); Compensation (Hajjar, Butler—Chair); Nominating & Corporate Governance (Butler, Bitar). Tassiopoulos is not listed on any board committee .
• Attendance: Each director serving during fiscal 2024 attended at least 75% of board and applicable committee meetings; policy expects all directors to attend the Annual Meeting .
• Board leadership: As of Nov 2024, Chairman was Tony Isaac and there was no Lead Independent Director . In Sept 2025, Zachary Witkoff accepted appointment as Chairman per investor nomination rights following the private placement .
• Executive sessions frequency: Not disclosed.

Fixed Compensation

• Director cash retainers/fees for Tassiopoulos: Not disclosed; ALT5 reports cash fees only for non-management directors for FY2023 (Bitar $18,000, Butler $30,000, Hajjar $14,400) . As CEO, Tassiopoulos would not typically receive non-employee director fees.
• CEO salary/bonus details for 2024: Not disclosed in the 2024 proxy (which covers FY2023); executive compensation table lists prior CEO Tony Isaac and CFO Virland Johnson for FY2023 .

Performance Compensation

• Equity awards: As of Oct 21, 2024, beneficial ownership includes 400,000 RSUs plus 20,000 common shares (total 420,000) (note (3)).
• 2024 Equity Incentive Plan: Authorizes 2,800,000 shares; permits stock awards, options, SARs, RSUs, and other stock-based awards with time- or performance-based vesting; non-employee director award limit capped at 100,000 shares (grant-date fair value basis) per year . Performance criteria may include financial and personal performance metrics at the company, unit, or individual level, with discretion to adjust for extraordinary items (b).

Other Directorships & Interlocks

• Board-level related party exposure exists with other directors/executives (e.g., Live Ventures shared services and agreements; VM7 disposal led by CFO; ICG note), but none are attributed to Tassiopoulos in the filings .

Expertise & Qualifications

• Core skills: M&A execution, capital markets, restructuring, strategic partnerships across cryptocurrency, technology, IT, healthcare, and gaming .
• Board qualifications: Financial, transaction execution, and strategic planning experience cited by ALT5 .
• Education: Not disclosed.

Equity Ownership

• Vested vs unvested breakdown: Not disclosed beyond RSU count as of Oct 21, 2024 (note (3)).
• Pledging: No pledging disclosures for Tassiopoulos; policy prohibits hedging by directors/officers/employees .

Governance Assessment

• Strengths:

  • Extensive M&A and restructuring background; experienced public-company executive and director, which can aid capital formation and strategic transactions .
  • Equity ownership (RSUs + stock) aligns incentives with shareholders (2).
  • Board maintains independent Audit, Compensation, and Governance committees without management members, supporting oversight separation .

• Risks and RED FLAGS:

  • Non-independence: Serving concurrently as CEO and director reduces board independence; ALT5 identifies other directors as independent, excluding Tassiopoulos .
  • Concentration of influence: 2025 private placement grants investor nomination rights (Chair + additional director) and potential >20% ownership, elevating control risk and misalignment potential; while not tied to Tassiopoulos specifically, it affects overall governance dynamics he operates within .
  • Disclosure gaps on pay-for-performance: No 2024 CEO pay mix, targets, or vesting specifics disclosed for Tassiopoulos, limiting assessment of pay alignment and performance rigor (note (3]).
  • Lock-up agreements for directors/officers may constrain liquidity but were adopted due to financing structure; they signal heightened financing/control negotiations impacting governance flexibility .

• Attendance and engagement: Minimum 75% attendance threshold met by all FY2024 directors; individual attendance percentages for Tassiopoulos not separately reported .

• Related-party transactions: None disclosed for Tassiopoulos; however, board-level related-party ties (Live Ventures shared services and ICG note) and prior sale to an entity led by the CFO warrant heightened committee vigilance even if not involving Tassiopoulos .

Overall: Tassiopoulos adds transaction and restructuring acumen but is not independent; investors should monitor compensation disclosure completeness, equity award structures, and the evolving board control environment post-2025 financing to assess board effectiveness and alignment.